塞普特纳生物

US · SEPN #2886 按市值排名上市于 2024

36.35 -1.10 -2.94%

实时 - 追踪5344个代码 - 心跳于57秒前 · 2026-10-16 19:30

✦ 量化股权信号计算方式说明

减持

最近一期（2026/Q3）披露持股的机构数量增加了1家。
机构持股总比例下降了6.0个百分点。

机构持股

机构持股比例: 99.03% -5.95pp
机构数量: 193 +1
数据截至: 2026/Q3 较上一报告期

持股变动 vs 资金流向

方向一致

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

VC/PE Fund47.48%

Mutual Fund37.64%

Hedge Fund9.04%

Public Company4.30%

Individual/Insider2.86%

Private Company0.35%

Government Pension Fund0.17%

主要股东截至 2026-08-12

Third Rock Ventures, LLC 22.02% · 10.28M 股

RA Capital Management, L.P. 11.79% · 5.50M 股

Driehaus Capital Management LLC 9.50% · 4.43M 股

Samsara BioCapital LLC 6.75% · 3.15M 股

BlackRock 4.14% · 1.93M 股

Artal Group S.A. 4.07% · 1.90M 股

The Goldman Sachs Group, Inc. 3.68% · 1.72M 股

Vanguard Capital Management, LLC 2.97% · 1.39M 股

Goldman Sachs Asset Management, L.P. 2.88% · 1.34M 股

Avoro Capital Advisors LLC 2.87% · 1.34M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 32次买入 · 18次卖出

姓名	职务	持股比例
Third Rock Ventures, LLC	--	22.02%
RA Capital Management, L.P.	--	11.79%
Jeffrey Finer	Chief Executive Officer	1.66%
Elizabeth Bhatt	Chief Operating Officer	0.37%
Uwe Klein	Senior Vice President of Biological Sciences	0.27%
R. Alan Ezekowitz	Director	0.25%
Daniel Long	Senior Vice President of Drug Discovery	0.21%
Gilbert Labrucherie	Chief Financial Officer	0.09%
Samira Shaikhly	Chief Human Resources Officer	0.00%
Shalini Sharp	Independent Director	--

内部人交易最近的 Form 4 申报记录

日期	姓名	职务	类型	股数	价格
2026-09-30	Daniel Long	Senior Vice President of Drug Discovery	Intent to Sell (Form 144)	-10,001	$39.13
2026-09-30	Samira Shaikhly	Chief Human Resources Officer	Intent to Sell (Form 144)	-12,592	$39.13
2026-09-07	Rajiv Patni	Chief Medical Officer	Other Derivative Acquisition	+275,000	$37.37
2026-08-31	Daniel Long	Senior Vice President of Drug Discovery	Derivative Exercise and Sale	-3,333	$2.76–37.83
2026-08-11	RA Capital Management, L.P.	--	Private Disposition	-1,493,000	$42.50
2026-08-11	Third Rock Ventures, LLC	--	Automatic Disposition	-147,200	$50.27–51.08
2026-08-10	Elizabeth Bhatt	Chief Operating Officer	Derivative Exercise and Sale	-25,000	$2.76–44.00
2026-08-02	Daniel Long	Senior Vice President of Drug Discovery	Derivative Exercise and Sale	-3,334	$2.76–34.68
2026-07-14	Elizabeth Bhatt	Chief Operating Officer	Derivative Exercise and Sale	-4,000	$6.81–33.99
2026-06-30	Daniel Long	Senior Vice President of Drug Discovery	Derivative Exercise and Sale	-3,333	$2.76–34.81
2026-06-28	Samira Shaikhly	Chief Human Resources Officer	Derivative Exercise and Sale	-2,178	$6.81–35.18
2026-06-25	R. Alan Ezekowitz	Director	Other Derivative Acquisition	+15,000	$37.34
2026-06-25	RA Capital Management, L.P.	--	Other Derivative Acquisition	+15,000	$37.34
2026-06-25	Shalini Sharp	Independent Director	Other Derivative Acquisition	+15,000	$37.34
2026-06-25	Jeffrey Tong	Chairperson	Other Derivative Acquisition	+15,000	$37.34
2026-06-25	Bernard Coulie	Independent Director	Other Derivative Acquisition	+15,000	$37.34
2026-06-25	Keith Gottesdiener	Director	Other Derivative Acquisition	+11,260	$37.34
2026-06-25	Jake Simson	Independent Director	Other Derivative Acquisition	+15,000	$37.34
2026-06-25	Abraham Bassan	Independent Director	Other Derivative Acquisition	+15,000	$37.34
2026-06-21	Daniel Long	Senior Vice President of Drug Discovery	Derivative Exercise and Sale	-15,000	$2.76–35.97

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 19:30:05 · 仅供参考，不构成投资建议，也未考虑您的具体情况。